# Question 29

**Type:** Basic Query - Mutual Exclusivity

**Question:** "Are mutations in CDKN2A, CDK4, and RB1 mutually exclusive in glioblastoma patients?"

**Answer:**

**URL**: https://www.cbioportal.org/results/oncoprint?Action=Submit&RPPA_SCORE_THRESHOLD=2.0&Z_SCORE_THRESHOLD=2.0&cancer_study_list=gbm_tcga_pan_can_atlas_2018&case_set_id=gbm_tcga_pan_can_atlas_2018_cnaseq&data_priority=0&gene_list=CDKN2A%2520CDK4%2520RB1&geneset_list=%20&genetic_profile_ids_PROFILE_COPY_NUMBER_ALTERATION=gbm_tcga_pan_can_atlas_2018_gistic&genetic_profile_ids_PROFILE_MUTATION_EXTENDED=gbm_tcga_pan_can_atlas_2018_mutations&profileFilter=0&tab_index=tab_visualize

This URL takes you to the OncoPrint view for CDKN2A, CDK4, and RB1 in the TCGA PanCancer Atlas 2018 Glioblastoma study. 

On this page, you can:
- Visually inspect the mutation patterns across samples to see if alterations in these genes tend to occur together or separately
- Use the "Mutual Exclusivity" tab to see statistical analysis of co-occurrence and mutual exclusivity between these genes
- View the OncoPrint to identify samples with alterations in each gene and assess overlap patterns

The mutual exclusivity analysis will provide p-values and odds ratios to help you determine whether these mutations occur independently or show significant mutual exclusivity in glioblastoma patients.

---

## Model Information
- **model**: us.anthropic.claude-sonnet-4-5-20250929-v1:0
- **temperature**: 0.0
- **max_output_tokens**: 1024
- **thinking_enabled**: False
- **thinking_budget_tokens**: 1024
- **response_time_seconds**: 8.203634302015416
- **agent_type**: cbio-nav-null

### Usage
- **input_tokens**: 558
- **output_tokens**: 387
- **total_tokens**: 945
- **cache_creation_input_tokens**: 0
- **cache_read_input_tokens**: 0

---

*Generated on 2026-02-05 01:37:14*